zepbound tirzepatide eli lilly Weight-loss drugs could see a shortage until 2025, makers predict Eli Lilly Study Finds Zepbound

We offer savings on Mounjaro and affordable alternatives to keep your treatment on track

We find that this advanced approach is particularly effective for those who have hit weight plateaus or require more intensive metabolic correction

Key safety risks include hypoglycaemia when combined with insulin or sulphonylureas, gastrointestinal interactions, pancreatitis, gallbladder disease, and dehydration-related acute kidney injury

Weight Reduction Following Randomized Withdrawal in Adults with Obesity or Overweight (Study 4) Overview of Study 4 Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks